burosumab   Click here for help

GtoPdb Ligand ID: 9292

Synonyms: burosumab-twza | Crysvita® | KRN-23 | KRN23 | N5KG1_C10_LH | UX-023 | UX023
Approved drug
burosumab is an approved drug (EMA & FDA (2018))
Compound class: Antibody
Comment: Burosumab (KRN23) is a fully human anti-FGF-23 monoclonal antibody. Anti-FGF-23 mAbs are considered suitable for prevention or treatment of diseases which are caused by hyperactivity of FGF-23 or for diseases whose pathology might be improved by controlling FGF-23 activity [1,4].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent US7883705, with the claimed antibody being abbreviated to 'C10' in the document (full identifier N5KG1_C10_LH) [11].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2018)  |  EMA (2018)
International Nonproprietary Names Click here for help
INN number INN
10301 burosumab
Synonyms Click here for help
burosumab-twza | Crysvita® | KRN-23 | KRN23 | N5KG1_C10_LH | UX-023 | UX023
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 647
Other databases
GtoPdb PubChem SID 318164811
Search PubMed clinical trials burosumab
Search PubMed titles burosumab
Search PubMed titles/abstracts burosumab